LONDON, April 27 Europe is moving towards becoming a knowledge-based economy. Keeping in line with this objective, the European commission has instituted the Framework 7 (FP7) programme. Launched to support the re-launched Lisbon strategy, FP7 focuses on research themes rather than the framework programmes of the past. It has been designed to meet some of the persisting challenges of raising Europe to match global excellence in research, thereby benefiting the European life science funding.
Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)
New analysis from Frost & Sullivan (http://www.pharma.frost.com), Life Sciences Funding - 2008, finds that the budget allocated in the FP6 was euro 2.51 billion and it witnessed a tremendous increase of 143 per cent, while the budget allocated for FP7 was euro 6.10 billion towards health from 2007 to 2013. The markets covered in this research service are Europe, the United Kingdom, Germany, France, Italy and Spain.
Advertisement
"The key to a knowledge-based economy lies in research, education, and innovation and this is what the European commission is targeting in order to reach the Lisbon goals," says Frost & Sullivan Consultant Shabeer Hussain. "The FP7 programme has incorporated European technology platforms and joint technology initiatives along with developing regions of knowledge and risk-sharing finance facility to nurture private investment in research."
The EU member states have committed to increase their R&D spending from the current 2 per cent of the gross domestic product (GDP) to 3 per cent by 2010. The increase in FP7 budgets convey this message towards the 3 per cent GDP goal and, in turn, urge the member states to tackle their research insensitivity.
Innovation-driven growth can be achieved through superior human capital and increased competitiveness on a global scale. Scientific publications and patents that are generated out of Europe are still fewer when compared to the United States and Japan. Research personnel with higher skill-sets will contribute more towards innovation and productivity. Therefore, investment in this area is of prime importance.
However, as Europe has several policies to promote research, innovation and entrepreneurship in the EU member states, the EU countries vary significantly in their abilities to develop technology and knowledge transfer. This deters growth prospects of the EU countries, thereby retarding the growth of Europe as a whole.
"The move towards innovation-based growth is very crucial to raise the European research level on the global arena and innovation is possible only with better partnerships among the private and public sectors," concludes Hussain. "Therefore, it becomes pivotal to form innovation clusters at the region level."
If you are interested in more information on Frost & Sullivan's research 'Life Sciences Funding - 2008', please send an e-mail to Katja Feick, Corporate Communications, at [email protected], with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.
Life Sciences Funding - 2008 is part of the Pharmaceuticals & Biotechnology Growth Partnership Services programme, which also includes research in the following markets: Mergers and acquisitions in Biotech Industry, Opportunities in Drug Delivery: Opening the doors to macromolecules, and Emerging therapeutic segments in the European Biopharmaceutical Markets. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.
Life Sciences Funding - 2008 (M48F) Contact: Katja Feick Corporate Communications - Europe P: +49 (0) 69 7703343 E: [email protected] http://www.frost.com Twitter: twitter.com/frost_sullivan
SOURCE Frost & Sullivan
